TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07722962: An Additional Phase 3, Multicenter Study of Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury

Sponsor: Kringle Pharma, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,314,560

Rescue Site Savings

+$7,448,752

Unlock Full NCT07722962 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07722962 Rescue Dossier →